APA (7th ed.) Citation

Weir, M. R., Chen, Y., He, J., Bookhart, B., Campbell, A., & Ashton, V. (2021). Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Diabetes Therapy, 12(12), 3167. https://doi.org/10.1007/s13300-021-01161-4

Chicago Style (17th ed.) Citation

Weir, Matthew R., Yen-Wen Chen, Jinghua He, Brahim Bookhart, Alicia Campbell, and Veronica Ashton. "Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes." Diabetes Therapy 12, no. 12 (2021): 3167. https://doi.org/10.1007/s13300-021-01161-4.

MLA (9th ed.) Citation

Weir, Matthew R., et al. "Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes." Diabetes Therapy, vol. 12, no. 12, 2021, p. 3167, https://doi.org/10.1007/s13300-021-01161-4.